Traders Nation (tm) - Financial News - National Guests - Stock Market Reports and Daily Updates
Use The Contact Button To Get A Clean Copy Of Our Logo - Thank you!



Kurt Schemers Host - Interviews:
Dr. David P. Summers, CEO of Endovasc, Inc.
(OTCBB: EVSC)




Shares O/S: 50,000,000
Float: 18,000,000
52-week Range: $0.055 - $3.01


CONTACT INFORMATION


Endovasc, Inc.
(OTCBB: EVSC)

Corporate Headquarters
550 Club Drive
Ste 440
Montgomery,TX 77316
P: (936) 582-5920
F: (936) 582-5996

Additional Contact
Dennis Evanson
(719) 534-0292
Email: devanson@adelphia.net

Website: Endovasc.com


Choose Your Listening Connection Speed:

THIS INTERVIEW HAS BEEN MOVED TO
THE ARCHIVES
You're in luck - it's available for download.
Click here to find out more.


28k or A Slow
*56k Connection
Audio Quality: Good
A Fast *56k Connection
Audio Quality: Better
100K - ISDN, T1, DSL, Cable, Connection
Audio Quality: Best
* A slow 56k connection will skip and re-buffer.
If this occurs click on the 28K connection.
Interview Information:
Interview Date: 06.26.03
Run Time: 13:12

Listen To Traders Nation LIVE Every Week Day Morning
Traders Nation 'LIVE' - The Fastest Growing Syndicated Radio Talk Show For Smallcap Stocks. Hosted by Kurt Schemers - More Info

The Company

About Endovasc, Inc. (OTCBB: EVSC)

Endovasc Inc. is a biopharmaceutical technology company established in 1996. The Company's mission is to bring to market drugs for the treatment of endocrine, inflammatory and cardiovascular diseases and to become a leader in drug delivery by producing unique and effective drug delivery systems.

Cardiovascular diseases are the major cause of mortality and morbidity in the western world. The cardiovascular and metabolic segment represents approximately 25% of the global pharmaceutical market. There are still significant medical needs in the area of hypertension, chronic renal disease, obesity, and congestive heart failure as well as in diabetes and lipid disorders. Clearly, new approaches are required to eliminate these treatment shortfalls, and there is an obvious need for rapid, cost-effective drug development - Endovasc's core competence!

Company Overview

Endovasc not only manages the drug development process, but also ensures the financing of all early development-related activities. Upon completion of the required phases of drug development, Endovasc intends to negotiate agreements with a pharmaceutical partner to cover the further development process and the commercialization of the drug.

Endovasc's focus is on cardiovascular and metabolic compounds with proven efficacy and identifies new indications for them, utilizing a proprietary drug delivery technology. The cardiovascular and metabolic markets account for more than USD 69 billion in sales volume per year. Cardiovascular diseases are the number one cause of death in the western world today. They account for 50% of deaths worldwide, nearly double of those caused by cancer, the second most prevalent cause of death. It is estimated that in the United States alone, the economic cost of cardiovascular diseases will reach over USD 350 billion in 2003.

Proof of Success
We have taken two cardiovascular drug candidates from pre-clinical concept through to Phase III human trial faster and cheaper than any other drug company ever. To understand the FDA Process, click here.

Trade Marks and Patents

PATENTS ISSUED OR LICENSED TO ENDOVASC
(with date of issuance)

07/09/2002 - Nicotine in Therapeutic Angiogenesis and Vasculogenesis
The invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.

05/28/2002 - Prosthesis with Biodegradable Surface Coating and Method for Making Same
The invention provides a prosthesis coated with a biodegradable, resorbable and biocompatible surface coating.

02/08/2001 - Nicotine Receptor Agonists in Stem Cell and Progenitor Cell Recruitment
The invention features methods for recruitment of bone marrow-derived stem cells (e.g., endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived stem cells (e.g., neutropenia).

06/27/2000 - Method for Making a Stent
The stent of the invention comprises a coil including a plurality of arcuate sections that alternate clockwise and counterclockwise directions around a central longitudinal axis. Each arcuate section includes a pair of curved turns joined by a cusp. More ==>

The Drugs

Liprostin is the liposome-encapsulated form of prostaglandin E-1 (PGE-1). A naturally occurring hormone, prostaglandin E-1 has been shown to be a potent vasodilator and platelet inhibitor, as well as an anti-inflammatory and anti-thrombotic agent. In the early 1970's, the U.S. Food and Drug Administration (FDA) approved prostaglandin E-1 (Alprostadil) for the treatment of ductus arteriosis of Botalli in neonates. Thus, much of the preclinical and clinical development and toxicology regarding the drug itself is known.

The Company believes it is the liposomal formulation of PGE-1 that will greatly change the dynamics of the drug and improve its therapeutic index, such that Liprostin may positively impact many areas of treatment, including post-myocardial infarction therapy, occlusive vascular disease, ischemic ulcers, critical limb salvage, claudicants, and arthritis that PGE-1 alone could not.

Clinical Trials
The Phase I clinical trial to establish the compound's safety, side effects and the maximum tolerated dose (MTD) in healthy volunteers was successfully concluded in January 2001. In discussions with the FDA, the Company learned that it could move directly to a Phase III clinical trial, since clinical data on PGE-1 has been established. The company submitted its protocol for FDA approval in the first calendar quarter of 2003. In this trial, set to begin the first calendar quarter of 2004, investigators will administer Liprostin as adjunct therapy in conjunction with peripheral angioplasty for patients suffering from critical limb ischemia or intermittent claudication.

In preparation for the Phase III trial, a 12-patient (Phase II) trial was initiated in January 2003 at Memorial Hermann Hospital by Drs. Richard Smalling and Satyendra Giri (Principle Investigator) of the University of Texas Medical School (Houston) to gain additional safety and efficacy data in patients suffering from either of the indications above.

Although FDA Phase III approval was obtained for the above indications, the company plans to conduct Phase II studies during 2003 to investigate additional indications for the use of Liprostin. The above trials address the moderate form of peripheral arterial occlusive disease (PAOD). The Company is conducting a Phase II trial involving 100 patients suffering from PAOD, but who do not require peripheral angioplasty in the third quarter of 2003. Sites for the study are located in Europe, Mexico and Brazil.

The purpose of this study is to determine if Liprostin could benefit patients which have the disease (PAOD) in earlier stages. Investigations will determine whether the drug can postpone or eliminate the need for surgical intervention. The number of patients that fall into the early stage of PAOD far exceed those requiring angioplasty therefore extending the medical benefits of Liprostin to a larger population base.



Angiogenix is the trademark name given to Endovasc's licensed drug, derived from the tobacco plant, from Stanford University. Commonly known as nicotine, it is the active form (-) s-isomer. Although often described as poisonous, the plant has a long history of medicinal use. The information regarding the pharmacology of nicotine is extensive, but research has focused on the negative effects of nicotine as a result of smoking cigarettes, which contain over 4,000 other constituents besides nicotine. Only recently have investigators begun to look at the potential beneficial effects of purified nicotine at doses far below the amount ingested by cigarette smokers and in an alternative formulation.

Research conducted in the laboratory of Dr. John Cooke at Stanford University revealed that the -(s) isomer of the nicotine molecule has angiogenic (new blood vessel growth) properties. In addition, the research revealed that the (-) s-isomer is very similar to the body's own neural transmitter, acetylcholine, and avidly binds to the cells' alpha receptor found ubiquitously on most, if not all cells in the body. Furthermore, the research found the very low doses (approximately 1000-fold lower than consumed by a pack-per-day smoker), had many therapeutic qualities, the most exciting being its abilities to recruit and mobilize "adult" stem cells to repair, rebuild and replace damaged or diseased mature cells, such as the development of new blood vessels and other tissue.



Pre-Clinical Trials
Endovasc has developed a liposomal formulation for nicotine and plans to develop other types of delivery systems to treat many diseases, including heart disease that otherwise would require coronary artery bypass grafting.

In 1998, nicotine was approved by the FDA as a therapeutic agent for cessation of smoking via transdermal or oral administration. It is marketed as Nicoderm skin patches and Nicotrol chewing gum. Thus the preclinical development and toxicology to support these products is well known.

In 1999, animal studies in mice and rabbits showed that nicotine could stimulate more new blood vessel growth in diseased limbs than any other angiogenic agent (bFGF, VEG-F, etc.) currently in development. These data were presented by Dr. Christopher Heeschen of Stanford University at the 49th Scientific Session of the American College of Cardiology (ACC), and the American Heart Association (AHA) Scientific Conference on Therapeutic Angiogenesis, respectively. In support of these initial results, animal studies in larger animals were conducted at Columbia Presbyterian Medical Center in New York by Dr. Daniel Burkhoff. Dog studies completed in January 2001 showed that nicotine could be safely injected into the myocardium. A feasibility study in pig hearts at Columbia Presbyterian also demonstrated safety and increased blood flow in various regions of the heart in several pigs. A larger study, which will test several means of delivery of nicotine in swine is underway at Washington Hospital Center in Washington D.C.

Endovasc anticipates seeking indications for Angiogenix for wound healing, skin grafting for burn patients to increase blood flow, for patients with chronic chest pain and chro nic leg pain, and induction of growth of new heart muscle cells after a heart attack.

Company Management

Dr. David P. Summers
Dr. David P. Summers serves as our Chief Executive Officer and Chairman. Dr. Summers has served in this capacity on a full-time basis since our inception and is primarily responsible for our operations as a whole. Prior to working with Endovasc, Dr. Summers founded American BioMed, Inc. and served as its President and Chief Executive Officer from 1984 to 1995.

Dr. Summers is a Fellow in the American College of Angiology, a Fellow in the International Society for Endovascular Surgery, as well as the inventor of several medical devices used to treat cardiovascular diseases. He is the author of 25 issued patents and has 8 patents pending. Prior to founding American BioMed, Dr. Summers assisted with the management of several corporations, including C.R. Bard, Inc., a manufacturer and distributor of cardiovascular medical products; Karl Stortz Endoscopy, an endoscopic instrument company; and Pall Corporation, a manufacturer and distributor of blood filtration products.

Dr. Summers holds an M.B.A. degree from Pepperdine University as well as a Ph.D. in International Economics from Kennedy-Western University. He is also a member of the New York Academy of Sciences, the American Association of Advancement of Science, the Houston Inventors Association, the European Vascular Society and the Society of Plastic Engineers.

M. Dwight Cantrell
M. Dwight Cantrell serves as our Chief Financial Officer, Treasurer and Director. Mr. Cantrell has maintained, and continues to maintain, a public accounting practice in the state of Texas since 1976. Mr. Cantrell is a public accountant. He has an extensive background in the banking and venture capital markets and is a member of the Association of Biotech Financial Officers. He has served as CFO since 1997.

Dr. Diane Dottavio
Dr. Diane Dottavio serves as our Director of Research and Development. Prior to joining us in March 2000, Dr. Dottavio served as Senior Scientist with Leukosite, Inc., from 1994 to 1996, and as Director of Laboratory Instruction and Research at the University of Houston, from 1996 to 2000. Ms. Dottavio holds a B.S. in Biology and a M.S. in Organic Chemistry from the University of New Mexico, as well as a Ph.D. in Biochemistry from the University of Texas.

DISCLAIMER

Compensation: $4,500 Endovasc, Inc. (bb: EVSC). Read Carefully and Think Clearly When Investing In Any Stock. TradersNation.com is an independent electronic publication providing both information and factual analysis on selected companies. The opinions and analysis included herein or in our audio programs are based on sources believed to be reliable and in good faith but no representation or warranty, expressed or implied, is made as to their accuracy, completeness or correctness. TradersNation.com, it's owners, employees or officers are not licensed brokers, broker dealers, investment advisers or underwriters.

This information read at TradersNation.com or it's newsletters or heard on "Traders Nation" is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. The foregoing discussion contains forward looking statements which are based on current expectations and differences can be expected.

The information contained herein or heard on "Traders Nation" may have been provided by the Company to TradersNation.com for information purposes only. Readers or listeners are urged to consult with independent financial advisors with respect to an investment in the issues mentioned herein. Investors should review a complete information package on the Company, which should include, but not be limited to, the Company's annual report, quarterly report, press releases, as well as all regulatory filings. All information contained in this report or audio program "Traders Nation" should be independently verified with the Company mentioned herein. Any opinions expressed in this report or heard on "Traders Nation" are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.

TradersNation.com nor its officers, directors, partners or employees / consultants accept no liability whatsoever for any direct or consequential loss arising from any use of this report or information heard on "Traders Nation". TradersNation.com affiliates, agents and/or family may have interests or positions in equity securities of the companies reviewed in this publication or presented on "Traders Nation", some or all of which may have been acquired prior to the dissemination of this report, and may increase or decrease these positions at any time.

Investing in growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.

TradersNation.com may or may not have purchased, sold or profiled via email stocks featured on it's website. TradersNation.com reviews and scours hundreds of stocks in a monthly period and can not participate in every find or send out every find via email. TradersNation.com feels that by doing so it would dilute interest in it's electronic emails or quality of the audio programming on "Traders Nation".

We encourage the reader to review the investing information available with the Securities and Exchange Commission ("SEC") at http://www.sec.gov and / or the National Association of Securities Dealers ("NASD") at http://www.nasdr.com. Readers can review all public filings by the Company at the SEC's EDGAR page.

The NASD has published information on how to invest carefully at its web site.

Finally, investing is a very serious business and you should treat it as one. Never invest money you aren't willing to risk to loss. There are many pitfalls to investing, your continued learning in the stock market is your best advantage.

Forward-Looking Statements
This news release may contain forward-looking statements, which involve risks and uncertainties. Accordingly, no assurance can be given that the actual events and results will not be materially different than the anticipated results described in the forward-looking statement. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include the Company's success in its business and operations; the activities of new or existing competitors, the ability to attract and retain employees and strategic partners, the ability to leverage intangible assets, the ability to complete new projects at planned costs and on planned schedules and adoption of the Internet as a medium of commerce, communications and learning. Investors are also directed to consider other risks and uncertainties discussed in documents filed by the company with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All logo's, copyrights, trademarks, and corporate identities respectfully and rightful belong to all owners listed or replicated herewithin.


Back To TOP



All original broadcast content, whether they be audio or video programs are copyright protected intellectual property of
TradersNation.com. Reproduction in whole or in part is strictly forbidden without written permission of the publisher. Linking to audio or video presentations on TradersNation.com is strictly forbidden without a license or agreement prior to capturing our copyright protected material.

TradersNation.com - A Financial Broadcasting Company. All Rights Reserved 2001 - 2017
© Associated Press. All rights reserved. Dedicated - All market data delayed 20 minutes.

Report A Site Problem Here

This Sites Disclaimer | Privacy | Contact | Contact Legal |
Spam | Advertise With Us

Connect with us today!
Traders Nation®
HOT TWEETS | Traders Nation® FACEBOOK | Kurt Schemers on FACEBOOK | Kurt Schemers DAILY TWEETS


Three Feet from Gold: Turn Your Obstacles in Opportunities
A fresh, modern look at the core theme of Napoleon Hill's revolutionary best seller. In this inspiring contemporary fable, a young writer sets out to interview business leaders and other influential figures about the importance of persistence in attaining your goals. Sharon L. Lechter, visits with Kurt Schemers on Traders Nation®.
Broadcast Interview

The Four Pillars of Profit-Driven Marketing: How to Maximize Creativity, Accountability, and ROI
Each year, billions of dollars are spent on marketing endeavors. Unfortunately, the vast majority of the money disappears into thin air, and marketing executives are left wondering if any of it came back in the form of ROI. Why? Because until now there has been no proven system for measuring marketing ROI. Leslie Moeller visits with Kurt Schemers
Broadcast Interview

Rethink: A Business Manifesto for Cutting Costs and Boosting Innovation
It's a totally human condition, a trap that ensnares virtually everyone. Just as when we tie a route to a destination so much so that when someone else takes a different route "why are we going this way?" it usually doesn't matter "how" you get there. This "how" trap also takes place at work, people intertwine "how" they do their job with the outcome of "what" they are doing that sometimes obvious decisions are masked, and missed. Ric Merrifields visits with Kurt Schemers on Traders Nation®.
Broadcast Interview

The Real Truth about Success
Wynn helps you discover your own personal advantage so you can stack the cards in your favor. visits with Garrison Wynn Kurt Schemers on Traders Nation®.
Broadcast Interview

Keeping The Millennials
How to attract, retain, and get the most from Generation Y employees A growing problem for many of today's businesses is the high turnover rate of Generation Y employees, also known as Millennials.
Broadcast Interview

The Next Evolution of Marketing
Find out what has changed about todays consumer that makes meaningful marketing more relevant...
Broadcast Interview

How to Be Useful: A Beginner's Guide to Not Hating Work
Megan Hustad dismantles the myths of getting ahead and helps you navigate the murky waters of office life. Humorous yet wise, irreverent yet marvelously practical, this book will help you learn. Megan Hustad visits with Kurt Schemers of Traders Nation®
Broadcast Interview

Collaboration
In Collaboration, author Morten Hansen takes aim at what many leaders inherently know: in today's competitive environment, companywide collaboration is an imperative for successful strategy execution, yet the sought-after synergies are rarely, if ever, realized. Morten Hansen visits with Kurt Schemers on Traders Nation®.
Broadcast Interview

Power of Who: You Already Know Everyone You Need to Know
Bob Beaudine believes Networking is not working for Americans any longer. This highly respected and well-connected head hunter shares his philosophy on what really works in identifying what your dream in life is and how to get it. Bob Beaudine visits with Kurt Schemers on Traders Nation®.
Broadcast Interview